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Abstract
In spite of recent advances with experiments on animal models, strongyloidiasis, an infection caused
by the nematode parasite Strongyloides stercoralis, has still been an elusive disease. Though endemic
in some developing countries, strongyloidiasis still poses a threat to the developed world. Due to
the peculiar but characteristic features of autoinfection, hyperinfection syndrome involving only
pulmonary and gastrointestinal systems, and disseminated infection with involvement of other
organs, strongyloidiasis needs special attention by the physician, especially one serving patients in
areas endemic for strongyloidiasis. Strongyloidiasis can occur without any symptoms, or as a
potentially fatal hyperinfection or disseminated infection. Th2 cell-mediated immunity, humoral
immunity and mucosal immunity have been shown to have protective effects against this parasitic
infection especially in animal models. Any factors that suppress these mechanisms (such as
intercurrent immune suppression or glucocorticoid therapy) could potentially trigger
hyperinfection or disseminated infection which could be fatal. Even with the recent advances in
laboratory tests, strongyloidiasis is still difficult to diagnose. But once diagnosed, the disease can be
treated effectively with antihelminthic drugs like Ivermectin. This review article summarizes a case
of strongyloidiasis and various aspects of strongyloidiasis, with emphasis on epidemiology, life cycle
of Strongyloides stercoralis, clinical manifestations of the disease, corticosteroids and strongyloidiasis,
diagnostic aspects of the disease, various host defense pathways against strongyloidiasis, and
available treatment options.

Background
In United States, strongyloidiasis is the most important
nematode infection in humans with a tendency towards
chronic persistent infection and with special characteristic
features of autoinfection, hyperinfection involving pulmonary and gastrointestinal systems, and disseminated
infection involving other organs [1-4]. Strongyloidiasis is
caused by a soil dwelling nematode helminth, Strongyloides stercoralis. This helminth resides in the small intestine of the human host. There is another species of same

genus, Strongyloides fuelleborni that can also cause human
infection but is mostly seen in African countries [4].
Infection with Strongyloides stercoralis was first reported in
the year 1876 in French soldiers working in Vietnam [4].
It took nearly 50 years for the complete elucidation of the
complex life cycle after the discovery of the parasite [4]
because of the rare and characteristic feature of autoinfection that occurs in the life cycle. Strongyloidiasis was first
described by Fulleborn in 1926 [5]. First reports of disseminated infection or hyperinfection date back to 1966
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when Cruz et al., and Rogers et al., independently documented the occurrence of fatal strongyloidiasis with
immunosuppression [6,7].
Though many advances have been made in the diagnosis
and treatment of strongyloidiasis, it still prevails as one of
the elusive diseases to tackle in the present day world.
Strongyloidiasis may have a spectrum of manifestations
ranging from the most common asymptomatic disease to
potentially life threatening hyperinfection syndrome and
disseminated disease. The patients, if symptomatic,
present with pulmonary and gastrointestinal symptoms.
Most of them are found to have strongyloidiasis after a
laboratory work up reveals an incidental finding of eosinophilia. This review article documents a case report with
symptoms along with review of the epidemiology, biology of strongyloidiasis, clinical manifestations of the disease including hyperinfection syndrome, effect of
systemic corticosteroids on strongyloidiasis, diagnostic
aspects of the disease, various pathophysiological mechanisms and host defense pathways regulating strongyloidiasis, and different options available to treat the
infection.

Case report
A 77 year old male veteran with past medical history significant for chronic obstructive pulmonary disease, coronary artery disease status post coronary artery bypass graft,
dyslipidemia, hypertension, and gastro esophageal reflux
disease was found to have an incidental eosinophilia with
12.4% eosinophils (absolute eosinophil count of 800
cells/mm3). He reported morning cough with small
amounts of thick mucus. He denied any epistaxis, difficulty in breathing, abdominal pain, diarrhea and constipation. He had lived in North East Tennessee for almost
30 yrs. He was an ex-smoker but had ceased to smoke
almost 30 years ago. On examination, he was an obese
male with periorbital edema. Auscultation demonstrated
a bruit just above the left sternoclavicular joint, but his
chest was clear to auscultation. A midline scar consistent
with previous coronary bypass grafting was seen. The rest
of the examination was essentially benign.
Due to eosinophilia, a complete evaluation was carried
out. Serological tests for strongyloidiasis were strongly
positive with antibody titer of 12.2 (Normal titer < 1.0).
Total serum levels of IgE and IgA were within-normal limits at 130 IU/mL and 243 mg/dL respectively and no
Strongyloides stercoralis larvae or eggs were found in the
stools as shown in the Table 1. He was given one dose of
ivermectin (200 micrograms/kilogram) and the repeat
labs, a month later, showed improved eosinophil percentage at 5.6% with a drop in the eosinophil count to 400
cells/mm3 along with drop in the strongyloid antibody
titer to 6.76 (Normal titer < 1.0) as shown in the Table 1.
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Three months after treatment, his respiratory symptoms
improved and one more dose of ivermectin (200 micrograms/Kg) was given for still elevated strongyloid antibody titer of 6.97 (normal titer < 1.0). Repeat labs, 4
months after the second treatment with ivermectin,
showed decreased strongyloid antibody titer to 5.0 (normal titer < 1.0) with no eosinophilia and thus indicating
a positive response to treatment (Table 1).
This is a case of mildly symptomatic chronic strongyloidiasis with very few respiratory symptoms consisting of
morning cough with small amounts of thick sputum, positive strongyloid antibody in the serum and negative larvae or eggs in the stool samples. This case also
demonstrates the effectiveness of ivermectin in the treatment of strongyloidiasis.

Epidemiology
Though parasitic infections are rare in the developed
world, sporadic cases of strongyloidiasis, toxocariasis, and
giardiasis happen especially in the endemic areas. Physicians should be aware of the endemic areas for strongyloidiasis because of difficulty in diagnosis and high potential
for fatal complications [2]. The parasite is mostly confined
to the tropics and subtropics infecting about 100 million
people in about 70 countries [4]. It is endemic in Southern, Eastern, and Central Europe, Islands of the Caribbean, Latin America, Sub-Saharan Africa and Southeast
Asia [1,4]. In non-endemic regions of the world, it is diagnosed in the prisoners of war (POWs) of World War II and
immigrants from endemic countries [8]. In the United
States, the infection is more prevalent in the Appalachian
region mainly Eastern Kentucky and rural Tennessee with
a prevalence of 4% and 2.5–3% respectively [1]. Males,
people of white race, residents of chronic care institutions
[9], and people working with soil (such as persons
employed in coal mines and farms) are at the greatest risk
of acquiring this disease [10]. A strong association is
noted between strongyloidiasis and concurrent immunosuppressive disorders such as HTLV-1 (Human T-cell Lymphotropic Virus – 1) or HIV (Human Immunodeficiency
Virus) infection and hematological malignancies [11-13].

Biology of Strongyloidiasis
The life cycle of Strongyloides stercoralis is distributed
between the free-living and parasitic cycles [10,14].
Strongyloides stercoralis is a soil dwelling nematode and
may take one of the two cycles depending on the prevalent
conditions and turns parasitic in adverse conditions [10].
The free-living cycle begins with the passage of the rhabditiform larvae in the stool, which, on reaching the soil,
molt under favorable conditions to become adult free living worms. These worms reproduce sexually and produce
rhabditiform larvae in turn, which then molt into filariform larvae. The latter forms infect the human host or
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Table 1: Laboratory Findings of Case Report

Lab Finding
Sodium (mEq/L)
Potassium (mEq/L)
Chloride (mEq/L)
Carbon Dioxide (mEq/L)
Glucose (mg/dL)
Blood Urea Nitrogen (mg/dL)
Creatinine (mg/dL)
Calcium (mg/dL)
Albumin (g/dL)
Total Protein (g/dL)
Alkaline Phosphatase (U/L)
SGPT (U/L)
SGOT (U/L)
Eosinophils (%)
Absolute Eosinophil Count (cells/
mm3)
Strongyloid Antibody by ELISA
(Index)
IgE (IU/mL)
IgA (mg/dL)
S. stercoralis Larvae/Eggs in Sputum
and Stools

Before Rx

One Month After 1stRx

Four Months After 2ndRx§

146
4.5
105
28
93
18
1.1
9.1
4.1
7.8
74
18
18
12.4
800

142
5.3
102
29
107
20
1.3
9.3
3.9
7.5
75
14
21
5.9
400

140
4.3
106
27
93
17
1.3
8.9
*
*
*
*
*
5.2
300

12.20

6.76

5.0

130
243
Negative

*
*
Negative

*
*
*

*, Not available; Rx, Treatment with Ivermectin; SGPT, Serum Glutamic-Pyruvic Transaminase; SGOT, Serum Glutamine-Oxaloacetic
Transaminase;
IgE, Immunoglobulin E; IgA, Immunoglobulin A; §, Second treatment with ivermectin is given 3 months after the first treatment;

develop into free living adult forms and continue the free
living cycle as shown in the Figure 1[10,14].
In the parasitic cycle, the rhabditiform larvae once passed
in the stool molt only twice and develop into filariform
larvae, which are infective to humans. When a susceptible
host is available, the infective filariform larvae penetrate
the intact skin, travel to the blood stream via subcutaneous lymphatics, and reach the pulmonary circulation.
Here they penetrate the alveolar membrane to become air
borne, ascend the tracheobronchial tree, are swallowed by
the host, reach the small intestine, molt twice more to
become adult parthenogenetic females. The females then
shed eggs which become rhabditiform larvae and are
passed out in the stools, to continue the cycle as shown in
the Figure 1[10,14].
Autoinfection is the one of the important characteristic
features of the life cycle of Strongyloides stercoralis. The various life cycle changes in the case of autoinfection are: the
rhabditiform larvae instead of being shed in the stool
molt twice in the body of the host (mainly in the intestine) to become filariform larvae that then penetrate the
intestinal wall or perianal skin and reach different organs
of the body leading to hyperinfection syndrome, if limited
to respiratory and gastrointestinal tracts or disseminated
infection with involvement of other organ systems.

Clinical manifestations of Strongyloidiasis
Strongyloidiasis can manifest in a wide spectrum of clinical features ranging from asymptomatic disease, disease
with mild initial symptoms, disease with chronic symptoms and acute exacerbation with hyperinfection or dissemination of larvae involving respiratory and
gastrointestinal systems or multiple organ systems respectively. Though fatal hyperinfection or dissemination can
occur, asymptomatic strongyloidiasis is the most common form of the disease [1,10]. The various clinical manifestations are shown in the Table 2.
1. Initial (acute) manifestations
The initial symptoms happen soon after the entry of the
infective filariform larvae into the human host from its
extraintestinal migration in the host. Though the acute
initial manifestations are not well described [15], the following symptoms are noted in some human infections:
serpiginous urticarial rash at the site of entry of the filariform larvae mostly in the legs [1,10,15], cough and tracheal irritation mimicking bronchitis from migration of
the larvae through the lungs [10], abdominal cramping
with bloating, watery diarrhea and sometimes constipation due to lodging of the larvae and maturation into
adult females in the small intestine of the host [10,16-18].
In fact, the most common complaint noted was abdominal bloating [17,18]. As these initial manifestations are
vague and mimic multiple other diseases, they are often
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Figure
Life
cycle1 of Strongyloides stercoralis
Life cycle of Strongyloides stercoralis. Complete life cycle of Strongyloides stercoralis with both parasitic and free living cycles
along with the cycle leading to autoinfection and hyperinfection syndrome. The cycle involving the mechanism of autoinfection
is shown on the right side of the figure with the cycle elucidating the concept of hyperinfection and disseminated infection on
the left side of the figure (adapted from: Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for
Disease Control & Prevention; Permission via phone taken from Ms. Melanie at (770) 488–4063).
misdiagnosed and treated symptomatically with the host
still harboring the parasite leading to a chronic state of the
disease.
2. Chronic manifestations
Even though the chronic form of strongyloidiasis is
asymptomatic in most cases, mild symptoms involving
pulmonary and gastrointestinal systems can happen
[10,19]. The various chronic manifestations include nausea, vomiting, epigastric pain with tenderness, intermittent vomiting, diarrhea, constipation, weight loss,
asthma-like symptoms, urticaria and distinctive larva currens rash from the subcutaneous migration of larvae
[1,10,20-26]. During the asymptomatic stage, the only
clinical finding could be eosinophilia [1,10]. Unless phy-

sicians have high index of suspicion based on various factors like residence in endemic areas or World War II
veterans, there is a high likelihood of misdiagnosis. This
requires physicians in the endemic areas to be more
aggressive in their investigational workup for eosinophilia. This idea is exemplified by the patient described
earlier.
3. Hyperinfection syndrome
Immunosuppression, either iatrogenic (for example, use
of systemic corticosteroids for chronic obstructive pulmonary disease or asthma, systemic lupus erythematosus,
rheumatoid arthritis, autoimmune hemolytic anemia,
chronic active hepatitis) [27], or due to intercurrent illness
such as HTLV-1 and HIV infection, organ transplantation,
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Table 2: Clinical Manifestations of Strongyloidiasis by Organ System

Organ System

Symptoms

Signs

Investigation

Skin

Pruritis, Eruption

CBC with differential counts

GI

Abdominal pain, Diarrhea, Nausea,
Vomiting
Wheezing, Cough, Hemoptysis,
Shortness of breath
Headache, Altered mental state,
Focal seizures, Coma
Urticaria, Anaphylaxis
Fever, Chills, Rigors

Urticaria, Angioedema, Larva
Currens, Eruption
Weight loss, Malabsorption,
Epigastric tenderness
Wheeze, Rales

Pulmonary
CNS
Immune/Allergic
Hematological
Other (Rare)

References

[1]

Meningeal signs, Disorientation

Stools for parasites, Strongyloid
antibody titer
Chest X ray, Sputum culture,
Sputum for parasites
Lumbar puncture and cultures

Urticarial rash, Larva Currens rash
Tachycardia, Bacteremia,
Septicemia, Eosinophilia

CBC with differential counts
Blood cultures, CBC with
differential counts

[65]
[1]

Peritonitis, Endocarditis,
Eosinophilic pleural effusion,
Eosinophilic granulomatous
enterocolitis

[1]

[1]
[39]
[40]

GI, Gastrointestinal; CNS, Central Nervous System; CBC, Complete Blood Count;

and other infectious diseases like kala-azar [28] can
increase the risk of hyperinfection syndrome in patients
with strongyloidiasis [1,4,21,29-36]. Hyperinfection syndrome is estimated to happen in 1.5 to 2.5% of the
patients with strongyloidiasis [37].
Hyperinfection syndrome is not exactly defined, but the
hallmark is an increase in the number of larvae in the
stool and/or sputum along with manifestations confined
to respiratory and gastrointestinal systems along with peritoneum [10]. The hyperinfection syndrome happens
from the enormous multiplication and migration of infective larvae especially in an immunosuppressed state. The
manifestations of hyperinfection syndrome are divided,
based on the system of origin, into intestinal and extraintestinal disease mainly involving the respiratory tract.
The intestinal manifestations include severe cramping
abdominal pain, watery diarrhea, weight loss, nausea,
vomiting and occasionally gastrointestinal bleeding [10].
Subacute intestinal obstruction can also be caused by
strongyloidiasis [38]. The extraintestinal manifestations
include mainly asthma-like symptoms such as cough and
wheezing, and others such as pneumonia and pulmonary
hemorrhage with diffuse bilateral infiltrates on the chest x
ray [1,10]. Rare conditions like eosinophilic pleural effusions [39] and eosinophilic granulomatous enterocolitis
[40] have also been reported in strongyloidiasis.
4. Other manifestations (including disseminated infection)
Even though, most cases of strongyloidiasis are asymptomatic or present with mild symptoms, fatal disseminated
infection with involvement of multiple organ systems
other than the respiratory and gastrointestinal systems as
in hyperinfection syndrome could also occur especially in
patients with immunosuppression from systemic steroids

[1,4]. Chronic infection and malnutrition also predispose
to systemic strongyloidiasis [19]. The mortality from disseminated infection could be up to 87% [1,41,42]. The
high mortality rate associated with hyperinfection syndrome and disseminated disease is frequently due to secondary bacterial infections [43,44]. The disseminated
infection occurs when the larval load increases, leading to
involvement of multiple organs thereby leading to various
manifestations along with severe respiratory and gastrointestinal features as mentioned above [19].
The cutaneous manifestations that could occur from dissemination include widespread petechiae and purpura
[22,45]. Occasionally this may also present as a pruritic,
erythematous, morbiliform eruption [15], or as an
intensely itching prurigo [23]. One of the most important
and potentially fatal complications that can occur is gram
negative bacteremia mainly from pathogens such as Streptococcus bovis [43], Escherichia coli, Streptococcus fecalis,
Klebsiella pneumoniae [1], or Enterobacter sp. [46] as they
become blood borne when the larvae penetrate the intestine [31,43]. Involvement of the central nervous system
may lead to headache, altered mental state, seizures and
rarely coma [1]. Gram negative bacterial meningitis has
also been frequently reported, especially in association
immunosuppression [43,47-51].

Corticosteroids and Strongyloidiasis
Multiple case reports indicate a potential increase in the
frequency of fatal hyperinfection or disseminated infection with corticosteroid therapy in patients with asymptomatic or mild strongyloidiasis [7,52-56]. Corticosteroids,
endogenous as well as exogenous, have been shown to
affect the immunity by increasing the apoptosis of Th2
cells, reducing the eosinophil count and inhibiting the
mast cell response there by leading to hyperinfection or
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disseminated infection [1]. It is also proposed that both
exogenous and endogenous corticosteroids increase
ecdysteroid like substances (naturally occurring sterols
with non-hormonal anabolic effects) in the body mainly
in the intestinal wall. These substances act as molting signals and lead to increased production of autoinfective
filariform larvae leading to hyperinfection and disseminated infection as shown in the Figure 2[41,57]. Siddiqui
et al., have demonstrated the presence of steroid receptor
on Strongyloides stercoralis, which could also play a role in
the pathogenesis of hyperinfection syndrome and more
systemic disseminated infection associated with corticosteroids, but this area needs further study [41].

Pituitary

ACTH (Native)

Exogenous
Steroids

The important conditions which can confuse the physicians in the diagnosis of strongyloidiasis include other
nematode infections. Strongyloidiasis, especially the
hyperinfection syndrome and more systemic disseminated infection, can sometimes mimic pneumonia [58],
polyarteritis nodosa [59], malignant mediastinal neoplasia [60], eosinophilic folliculitis [61], relapse of lymphoma [62], primary intestinal lymphoma [38], flare up
of systemic lupus erythematosus [63], peptic ulcer disease
[64], and ulcerative colitis or crohn's disease [40,64].
Due to the asymptomatic nature of intestinal strongyloidiasis, and the risk for hyperinfection, screening of the
population in endemic areas especially before considering

Clinical Manifestations
Involving the
Respiratory and
Gastrointestinal
Systems & Fatality
↑ No. of
Filariform Larvae
↑ Molting
Signals
↑ Ecdysteroid like
Substances

Adrenal
Gland
(Cortex)

Diagnostic aspects

Altered
Immunity

Altered Mast Cell Function

↑ Corticosteroids

T cell Dysfunction
CD4+ Th2 Cell with
Steroid Receptor
(GCR)

↑Apoptosis

Figure 2
Corticosteroids
and strongyloid hyperinfection syndrome
Corticosteroids and strongyloid hyperinfection syndrome. The pathophysiological pathway showing the mechanism of
corticosteroids leading to strongyloid hyperinfection syndrome and disseminated infection. Corticosteroids along with cortisol
act on specific receptors called glucocorticoid receptors (GCRs) available on CD4+ Th2 cell membrane causing apoptosis and
thus T cell dysfunction. Corticosteroids also increase ecdysteroid like substances in the body which act as molting signals for
eggs and rhabditiform larvae, leading to increased number of filariform larvae [41,57].
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immunosuppressive therapy is important. There is no one
ideal screening or diagnostic test, making strongyloidiasis
a difficult infection to detect in humans [18,65].

malin-ether concentration method for larvae to be less
sensitive in detecting the disease when used alone, especially in non-endemic regions [18].

The most important laboratory finding seen in patients
with strongyloidiasis is eosinophilia [65]. Eosinophilia is
shown to be 93.5% sensitive with a specificity of 93.1% in
high risk populations [2]. But it is also shown that the
eosinophil count if used alone is not sufficiently sensitive
to screen for strongyloidiasis [18,66] especially in patients
with chronic infection who can have low or normal eosinophil counts [65], in people returning from developing
countries [66], and in some cases of hyperinfection syndrome and disseminated strongyloidiasis. However,
increased peripheral eosinophilia in the case of hyperinfection syndrome could be considered as a good prognostic factor [10]. Eosinophilia is not a cost effective strategy
compared to the stool examinations with agar plate culture method and serological testing in detecting strongyloides infection in humans [67].

Microscopic examination of stool specimens is done for
strongyloid larvae. This can be done in the following different ways: 1) Simple direct smear with a sensitivity of 0–
52% [8], 2) Formalin-ether concentration method with a
sensitivity of 13–55% [8], 3) Harada-Mori filter paper culture method with almost equal sensitivity to the above 2
methods [74,75], and 4) Agar plate culture technique with
higher sensitivity of 78–100% [8]. Of all the mentioned
methods, multiple studies have shown detection of
strongyloides larvae in stool specimens is more effective
and accurate with agar plate culture technique [4,73-75].
Biopsy with duodenal intubation and Enterotest™ are
rarely used, though they have high sensitivity, because
they are very cumbersome [76].

Diagnosis of strongyloidiasis could be done by serological
methods especially in asymptomatic patients with eosinophilia (as in the patient described in this report) or
mildly symptomatic patients. These serological tests are
also shown to be useful in the diagnosis of strongyloidiasis even in immunocompromised individuals [68]. The
serological methods determine the presence of strongyloid antibody in the serum of the human hosts. The antibody could be determined by the following methods: 1)
Enzyme-Linked Immuno-Sorbent Assay (ELISA) [69,70],
2) Gelatin Particle Indirect Agglutination (GPIA) [69],
and 3) Western Blot Analysis (WBA) [8].

Experiments on mice and other animal models have
yielded information about the immune mechanisms
against nematode parasites and they have also shown that
mechanisms differ depending on the host species and the
parasite strain used [77]. These experiments support the
theory that both T and B cell mediated immunity are
required in the immune response to Strongyloides stercoralis [78-80].

Huaman et al., in their study showed that both ELISA and
GPIA are useful in the diagnosis of strongyloidiasis with
sensitivities of 74.1% and 98.2%, respectively and specificity of 100% for both studies. As low titers of strongyloidspecific antibodies are noted in hyperinfection along with
a low or normal eosinophil count, GPIA is more sensitive
than ELISA in detecting the specific immunoglobulin in
cases of chronic infection and hyperinfection [69]. New
strongyloides-specific antigens are being discovered that
may help in the immunodiagnosis of strongyloidiasis in a
more sensitive and effective way [71].
The diagnosis of strongyloidiasis can also be made very
reliably by observing strongyloid larvae in stool or sputum specimens. But these tests are not accurate as there is
fluctuation in the rate of larval excretion especially in
stools [8] decreasing the efficacy and accuracy of these
tests [72]. Repeated multiple stool specimens should be
analyzed to increase the efficacy of the test in the presence
of strong suspicion of strongyloidiasis [2,8,73]. Sudharshi
et al., in their study have noted stool examinations by for-

Pathophysiological mechanisms and host
defense pathways regulating Strongyloidiasis

Increased serum IgE (Immunoglobulin E) levels, eosinophilia in the peripheral blood, increased numbers of
mast cells in the intestine, and hyperplasia of goblet cells
of the intestine are the responses noted in the nematode
infections of the gastrointestinal tract [81-83]. Eosinophils, intestinal mast cells and goblet cells, IgE, type 2
helper T (Th2) cells and cytokines such as IL-4 (Interleukin-4), IL-5 (Interleukin-5), IL-6 (Interleukin-6), IL-9
(Interleukin-9), IL-10 (Interleukin-10), and IL-13 (Interleukin-13) are shown to be the mediators of immunity
against Strongyloides stercoralis [1,83-91]. The various types
of defense mechanisms against strongyloides larvae are
shown in Table 3.
There are 2 broad types of defense mechanisms in the case
of S. stercoralis – mechanisms against the filariform larvae,
which infect the human host for the first time and mechanisms against the host adopted larvae that cause autoinfection. The following defense mechanisms may function
in one or both of the above types.
T cell mediated immunity, especially involving CD4+
cells, has been shown to be important in the defense
against Strongyloides stercoralis larvae using a rodent model
[92]. In humans, as the infection is more prevalent in
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Table 3: Various Types of Immunity in Strongyloidiasis

Type of Immunity

Mediators

Reference

T Cell Mediated Immunity
Th2 Cellular Immunity
Humoral Immunity
Antibody Dependent Cellular Cytotoxicity
Mucosal Immunity
Complement System

CD4+ Cells
IL-4, IL-5
IgM, IgG, IgA, IgE
IgM, IgG, Eosinophils, Neutrophils
Mast Cells, Goblet Cells
Complement activation

[11,12,92]
[77,81]
[95,98]
[91,98,99]
[81,82,87]
[99]

CD, Cluster Differentiation; Th2, Type 2 T Helper; IL, Interleukin; IgM, Immunoglobulin M; IgG, Immunoglobulin G; IgA, Immunoglobulin A; IgE,
Immunoglobulin E;

hematological malignancies and HIV infected people, it is
proposed that T cell immunity involving CD4+ cells plays
a role in the defense against strongyloidiasis [11,12]. In a
study reported by Trajman et al., the detection of T celldependent serum-specific IgA and IgE antibodies indicates the importance of T cell immunity in S. stercoralis
infection [84]. It has been shown that contact with
immune cells is required for immunity against strongyloides larvae (as reported in a rodent model using the
human parasite, Strongyloides stercoralis) [93].
Type 2 T helper (Th2) cells that stimulate eosinophils, IgE
production, mast cells, and goblet cells by producing IL-4,
IL-5, IL-9 [91], IL-10 and IL-13, are important in the
defense against strongyloides infection [1,81,84,91,92].
This has been shown, for example, in people with coinfection with HTLV-1 which decreases Th2 cell-mediated
immunity, thereby increasing the risk for hyperinfection
syndrome or disseminated infection [94].
In severe strongyloidiasis, no significant change in the T
cell numbers is noted compared with asymptomatic or
mildly symptomatic disease [95] indicating the importance of other immune mechanisms. It is also reported
that infected patients elicit a decreased lymphocyte blastogenic response to larval Strongyloides stercoralis antigens
suggesting presence of factors in the serum of patients that
are inhibitory to the function of cell mediated immunity
[84,86].
Controversy exists over whether one cytokine is more
important than another in the resistance against nematodes even in animal studies. IL-3 (Interleukin-3) has
been shown in multiple previous studies as a potent mast
cell synthesis stimulator. But, Kobayashi et al., using a
rodent model showed Strongyloides venezuelensis can stimulate mastocytosis without IL-3 indicating a role of other
mechanisms [90]. IL-4 is an important regulator of IgE
antibody production and mast cell activation [88]. Urban
et al., using an animal model with Heligmosomoides polygyrus have shown that IL-4 is an important factor in the
defense against gastrointestinal nematode infections [88].
Watanabe et al., showed the importance of IL-4 in the

induction and maintenance of intestinal mast cells with
Strongyloides ratti in mice [81]. As no human studies are
available indicating the importance of IL-4, and with the
exact role of IL-4 in helminth infection being unknown, it
would be premature to consider IL-4 as an important factor in the defense against strongyloidiasis [91]. IL-5 is
important in differentiation, maturation and survival of
eosinophils [77] by regulating the eosinophil precursors
in the bone marrow [88]. Herbert et al., showed the possible roles played by IL-5 in innate as well as adaptive
immunity against human parasite larvae in mice, by
inducing eosinophil production during innate immunity
and IgM (Immunoglobulin M) production in the adaptive
immune response. Porto et al., in their effort to demonstrate the effect of HTLV-1 in patients with strongyloidiasis, noticed increased IL-5 in patients with strongyloidiasis
[96]. These studies involving the human parasite-rodent
models and human parasite-humans indicate a very
important part played by IL-5 in the immunity against
strongyloides infection especially by inducing eosinophil
differentiation, maturation and survival.
Humoral immunity mainly includes the defense mechanisms with the production of immunoglobulins by
plasma cells. Herbert et al., in their experiment with mice
using human parasites, showed that B cells play no part in
the defense against primary infection but play an important role in subsequent challenge infections with a resultant increase in parasite specific immunoglobulin, mainly
IgM [78].
Immunoglobulins are shown to play an important role in
the defense against strongyloidiasis. Even though strongyloid-specific antibodies are noted in the infection, they do
not provide the required immunity without the help of
other defense mechanisms. There is increasing evidence
that IgE mediated activation of accessory cells can play an
important role in the resistance against parasitic infection
[82]. Even though IgE is increased in the helminth infections, most of that is non-specific and may block the
development of the host defense mechanism by saturating IgE receptors on effector cells [91]. Brigandi and coworkers while experimenting with mice and Strongyloides
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stercoralis noticed IgE along with IgA to have no effect on
killing of infective larvae. In humans, IgE antibodies are
specifically formed against filariform larvae [97]. However, Badaro et al., showed that no correlation exists
between the total IgE, specific IgE and IgG (Immunoglobulin G) antibody quantities and the clinical severity of
strongyloidiasis. As humans differ from rodents and
experimental models, IgE-mediated anti-parasite immunity is controversial [91]. As there is an increase in IgE levels in strongyloides infection both in human subjects with
the infection as well as in experimental models, it is likely
that IgE plays a pivotal role, but the exact nature of this
role is currently unclear. However, determination of IgE
levels with radioallergosorbant test (RAST) could be helpful in the immunological evaluation of the patient [97].
As it is shown in animal models, IgG and IgM can passively transfer immunity against human parasite larvae in
the presence of a well functioning complement system
and neutrophils [77,93,98,99]. In severe strongyloidiasis,
IgA (Immunoglobulin A), IgG and IgM levels were significantly lower compared with asymptomatic or mildly
symptomatic strongyloidiasis [95]. It is also shown, in
mouse model with the human parasite, host adopted or
autoinfective filariform larvae have different surface antigens and IgM specific for primary infective filariform larvae is not effective against autoinfective larvae [100]. Lack
of host response to autoinfective larvae along with lack of
specific IgM antibodies could play a role in autoinfection
and thus in hyperinfection syndrome and disseminated
infection.
Antibody Dependent Cellular Cytotoxicity (ADCC) is
proposed as one of the defense mechanisms against the
nematodes especially in rodent experiments involving
human parasite larvae with IgE activation of eosinophils
[1,91] as well as IgG activated ADCC involving neutrophils [98]. As shown in the experiments on mice with
Strongyloides stercoralis larvae, ADCC may play a role in the
immunity against live infective larvae but not against
injected larval antigens [98,101]. However, Kerepesi et al.,
with experiments on mice and human parasite larvae
indicated ADCC is not required for larval killing [102].
Insufficient and controversial results do not substantiate
the role played by ADCC in the immunity against strongyloides, requiring further research to demonstrate its
importance.
Eosinophils are bone marrow derived granulocytes which
can secrete highly toxic substances contained in their
granules in the wake of infections and allergic reactions
[82]. Eosinophil production is activated by IL-5 released
by the Th2 cells and in turn eosinophils also release lymphocyte active cytokines that can stimulate and affect the
functioning of lymphocytes [82,103]. In experimental

http://www.clinicalmolecularallergy.com/content/4/1/8

studies using mice and human parasite larvae, an increase
in eosinophils is seen with parasite killing in nematode
infections [93,104]. Eosinophils seem to be directly
involved in the destruction of helminths and their migrating larvae as they penetrate the intestinal mucosa [83,91]
as shown in the animal studies, especially in mice in the
presence of specific antibodies [82,91]. Though eosinophils can cause destruction of helminth larvae, especially host-adopted filariform larvae [104], it is not
sufficient for complete protection [91]. In humans, their
role in the defense against S. stercoralis is controversial.
Even though eosinophils are noted to be important in
defense against Strongyloides stercoralis, significantly lower
eosinophil counts are noted in severe strongyloidiasis
[95] indicating a possibility of suppression of eosinophils
especially in disseminated infections. Neutrophils are
important in immunity against infective larvae of Strongyloides stercoralis in mice [98,99] which could also play a
role in human strongyloidiasis. They are shown to have a
controversial effect through the ADCC mechanism with
the help of IgG as mentioned earlier.
All nematode infections elicit the same intestinal phenomena with different effector mechanisms [81,91].
Strongyloides infections are difficult to eradicate completely mainly because of autoinfection. As this nematode
resides in the small intestine [1,10] of the human beings,
local mucosal immunity along with inflammatory
changes may play a role in their eradication [87]. Many
studies are done on mice to evaluate the mucosal
responses to gastrointestinal nematode infections. There
are different mechanisms in which the local mucosal
immunity defends against the infection manifesting in
different forms like expulsion of the adult worms,
decrease in the length of the worms, reduction in fecundity of the female worms, and failure of infective larvae to
establish [87]. The above said mucosal defense mechanisms are mediated by both humoral and cell mediated
immunity.
Studies with animal models and Strongyloides ratti showed
the important role played by goblet cells in the expulsion
of the parasite from the GI tract [81]. These goblet cells
were induced by IL-13 secreted by Th2 cells [81]. Intestinal
mastocytosis, induced by IL-3 [90], is observed in many
nematode infections. Mast cells are also shown to play an
important role in the defense against parasite infestations
[82] and are considered as the effector cells against Strongyloides species even in humans [90]. Experiments on mice
with Strongyloides species have shown the importance of
intestinal mastocytosis in the expulsion of the worm from
the gastrointestinal tract.
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Trajman et al., in their study, have noted that intestinal
response in the form of expulsion is seen in rodent experiments and could not be confirmed in human beings. No
change in the jejunal morphology, different T cell subset
numbers, mast cells, eosinophils and goblet cells were
noted along with lack of cell activation in the mucosa as
shown by the absence of CD25+ cells. However, they
noted a decrease in the number of mature macrophages
and dividing enterocytes in the crypts of the intestinal wall
[84]. Absence of immune response might be the reason
for preservation of architecture of the mucosa and absence
of immune mediated diarrhea in Strongyloides stercoralis
infection. This indicates the controversial role of the
mucosal immunity played against strongyloides infections necessitating further studies especially involving
human subjects.
Activation of both classical and alternate pathway of the
complement system [102,105] with chemoattraction and
binding of the granulocytes to the infective larvae has also
been shown to play a role in the immunity against S. stercoralis in mice [99,102]. Machado et al., with their experiment on mice have indicated the potential role played by
the leukotrienes as immunostimulants against strongyloides [106]. But the specific role of complement and leukotrienes in strongyloides infections is not proven even in
experimental animals.

Management
Albendazole, mebendazole, thiabendazole and ivermectin have shown to be effective on Strongyloides stercoralis
[107-109]. Recently, there has been a change in the treatment of strongyloidiasis with more studies showing ivermectin as the drug of choice. In a randomized control trial
done by Gann et al., comparing ivermectin with thiabendazole, the investigators showed that one dose of ivermectin is as effective as prolonged thiabendazole in the
treatment of strongyloidiasis with less adverse side effects
[107]. Ivermectin is shown to be very effective in the treatment of strongyloidiasis [109] as well as in the treatment
of hyperinfection syndrome with predisposing conditions
like AIDS (Acquired Immunodeficiency Syndrome) [33].
Treatment of strongyloidiasis has been shown to improve
the cutaneous manifestations [25] as well as asthma-like
symptoms associated with the nematode [110].
In Strongyloides stercoralis-infected patients presenting with
asthma-like symptoms, physicians should be cautious in
using leukotriene synthesis inhibitors. The use of leukotriene synthesis inhibitors may worsen the infection as leukotrienes are shown to play a potential role in the
immunity against strongyloides infection in murine animal models [106] and possibly in human subjects. More
research is needed in this aspect before limiting the use of
leukotriene synthesis inhibitors.
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Relapses, especially involving gastrointestinal tract, were
noted even after treatment of strongyloidiasis. For the
chronicity of the infection and possibility of occurrence of
dangerous exacerbations, diagnostic surveillance is recommended to prevent the occurrence of fatal hyperinfection [65]. The surveillance could be done in the form of
repeat eosinophil counts along with serological surveillance with serial antibody titers and multiple stool specimens for larvae.
The efficacy of the treatment depends on many factors like
immunodeficiency, co-infection with HTLV-1, use of corticosteroids and presence of bowel ileus that can decrease
the efficacy of the drugs used in the treatment of strongyloidiasis [19,94]. Monitoring the response to treatment
could be very difficult with detection of strongyloid larvae
in the stool specimen because of the inconsistent shedding of the larvae [72].
Loutfy et al., in their study have suggested that serological
tests mainly EIA with serial eosinophil counts could be
used to monitor the response to the treatment [76]. In a
study involving 3 patients with strongyloidiasis, serial
total IgE levels decreased after effective treatment indicating a possibility of using serial total IgE levels in monitoring the response to treatment [111]. As no prospective
studies were done in this direction, it would be very difficult to determine which test would be the test-of-cure for
strongyloidiasis [76]. Failure to respond to treatment or
recurrence of hyperinfection syndrome is an indication to
look for latent or asymptomatic HTLV-1 infection [, ].
Personal hygienic measures like proper protection of skin
to prevent contact with infected soil, community level
hygienic measures like proper disposal of human excreta,
community education about protective and hygienic
measures, and prompt treatment of diagnosed cases
would help in the prevention of the disease [44].
Vaccines, which are effective against infective stage filariform larvae could be a possibility based on the experimental evidence in mice, especially if composed of
multiple antigens [98,99,102,104]. Further studies
mainly involving voluntary human subjects are required
to confirm this possibility.

Conclusion
Strongyloidiasis is a nematode infection with a tendency
to become chronic with fatal complications of hyperinfection syndrome and disseminated infection along with a
host of other potential complications like gram-negative
bacteremia and meningitis. As the infection is mostly
chronic and asymptomatic, and there is no specific ideal
test to diagnose the disease, it still tends to be a diagnostically elusive disease even in the present era.
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Non-endemic regions of the world have endemic pockets
for strongyloidiasis, like rural Tennessee and Kentucky in
the USA, making the disease more important especially in
view of potentially fatal hyperinfection syndrome and disseminated infection. As most cases of hyperinfection syndrome and disseminated strongyloidiasis happen in
immunocompromised individuals, especially those who
are taking systemic steroids, physicians in the endemic
areas should be aware of the bizarre manifestations of the
disease that can mimic other diseases leading to misdiagnosis and medical errors.
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